

aspho

American Society of
**PEDIATRIC
HEMATOLOGY
ONCOLOGY**



24th Annual Meeting ■ April 13–16, 2011
Baltimore, MD ■ Hilton Baltimore

The 24th Annual Meeting will offer pediatric hematologists/oncologists a concentrated and high-quality continuing medical education program, covering a broad spectrum of clinical topics and a growing program of original science presentations. In addition to presenting the latest clinical discoveries, the meeting offers you an opportunity to network with colleagues, acquire new skills, meet the experts, and focus on advancing your career to the next level, no matter where you are on the career ladder.

The 2011 meeting will feature

- two sessions on patient safety and quality improvement
- pediatric highlights of the BMT Tandem Meetings
- a palliative care workshop focused on innovations in pain management
- Young Investigator sessions, including a workshop on developing successful mentored career grant applications
- five platform sessions
- Battle of the Superstars.

Objectives

- Comprehend new information in pediatric hematology/oncology, including the latest in basic and clinical research.
- Apply knowledge gained in all areas of pediatric hematology/oncology investigation and practice.
- Assemble a network of professional colleagues with whom you can solve problems, share experiences, and provide mutual professional support.

Continuing Medical Education (CME) Credit

The ASPHO 24th Annual Meeting will offer continuing medical education credit. Credit will be awarded for those sessions attended and evaluated. A certificate will be issued upon completion of the evaluation.

ASPHO is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ASPHO designates this activity for a maximum of 23.25 *AMA PRA Category 1 Credits*[™]. Physicians should claim credit commensurate with the extent of their participation in the activity.

ASPHO offers its meeting evaluation in an online format. Meeting registrants can access the evaluation by visiting the ASPHO website, www.aspho.org, and clicking on the Evaluation Form link located on the home page. The online evaluation may be completed during the meeting or after attendees have returned home. Participants will receive their CME certificate immediately when they submit their evaluations online. We encourage all attendees to complete this evaluation whether or not they are seeking CME credits. For more information, please visit the ASPHO website or call 847.375.4716.

Disclosure

It is the policy of ASPHO that the planners, faculty, and provider disclose the existence of any relevant financial interest or other relationships they may have with the manufacturer(s) of any commercial product(s) or services relating to the topics presented in the educational activity. ASPHO requires disclosure of the intent to discuss unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose. It is the responsibility of the Program Committee to review potential conflicts of interest as submitted in the disclosure form and resolve such conflicts. Resolving the conflict ensures that the content of the activity is aligned with the interests of the public. Detailed disclosure information will be published in conference materials. Learners will also be informed when no relevant financial relationships exist.


Disclaimer

The material presented in this activity represents the opinion of the speakers and not necessarily the views of ASPHO.

Acknowledgment

ASPHO gratefully acknowledges the following organizations for their support of the annual meeting:

- Names Family Foundation
- American Society for Blood and Marrow Transplantation.



Schedule at a Glance

Wednesday, April 13

5:30–7 pm

Concurrent Workshops

(W01) Hemostatic and Thrombotic Consultations in Pediatric Critical Care

(W02) Molecular Classification of Brain Tumors—Are We There Yet?

7:30–9 pm

Corporate Forum Dinner Symposium*
Division Directors' Meeting

Thursday, April 14

7–8:30 am

Concurrent Workshops

(W03) Preparing Successful Mentored Career Grant Applications 

(W04) Menorrhagia and Bleeding Disorders

8:45–10:45 am

Presidential Symposium

(S01) Above All, Do No Harm: Patient Safety and Quality Improvement in the Life-and-Death Moments of Pediatric Hematology/Oncology

11:15 am–12:15 pm

Concurrent Platform Sessions I

12:30–2 pm

One-on-One Young Investigator Career Workshop Lunch 
(Advance registration is required.)

2:15–4:15 pm

Symposia

(S02) Young Investigator Symposium 

(S03) What the Dickens—It's ALiver Twist! Childhood Liver Cancer Symposium

4:45–5:45 pm

Young Investigator Award Presentations 

Plenary Platform Session

5:45–6:45 pm

Author-Attended Poster Session A

5:45–7:30 pm

Grand Opening Reception with Exhibits and Posters

7:30–9 pm

Corporate Forum Dinner Symposium*
Training Program Directors' Dinner Meeting

(Advance registration is required.)

Friday, April 15

7–8:30 am

Concurrent Workshops

(W05) Closing the Gap on Palliative Care

(W06) Antimicrobial Prophylaxis in Pediatric Oncology: What's Old, What's New, and What's Coming?

8:45–10:45 am

Symposia

(S04) Translational Medicine: Bone Marrow-Derived Stem Cells and the Tumor Microenvironment

(S05) Beyond the Big Three (Heparin, Warfarin, and Aspirin)—Newer Antithrombotic Agents in Development: Relevance for Pediatric Hematology

10:45–11:15 am

Break with Exhibits and Posters

11:15 am–12:15 pm

Concurrent Platform Sessions II

12:30–1:45 pm

Author-Attended Poster Session B

1:45–3:45 pm

Symposia

(S06) Myeloid Malignancies: Molecular Pathogenesis and Targeted Therapies

(S07) Not Ravens But Dodos: Rare Birds in Pediatric Hematology

3:45–4 pm

Break with Exhibits and Posters

4–6 pm

Business Meeting and Award Presentations

- President's Remarks
- Frank A. Oski Memorial Lecture
- Distinguished Career Award

6–6:30 pm

Award Reception

6:30–7:30 pm

Battle of the Superstars

Saturday, April 16

7–8:30 am

Concurrent Workshops

(W07) Update on the Diagnosis, Evaluation, and Management of Histiocytic Disorders

(W08) Practice Workshop: Improving Safety in Pediatric Hematology/Oncology

8:45–10:45 am

Symposia

(S08) New Aspects of Neuroblastoma Treatment

(S09) Pediatric Highlights of the BMT Tandem Meetings

11:15 am–1:15 pm

Symposia

(S10) Transfusion Medicine Problems and Solutions for the General Pediatric Hematologist/Oncologist

(S11) Many Pathways in Pediatric Hematology and Oncology Lead to mTOR



*For more information on corporate forum symposia, see page 12.

Educational Program | Wednesday, April 13

5:30–7 pm

Concurrent Workshops

(W01) Hemostatic and Thrombotic Consultations in Pediatric Critical Care

Moderator: Donald L. Yee, MD

Bleeding and clotting complications in critically ill patients are clinically important and universally encountered by pediatric hematology/oncology (PHO) providers in the inpatient consultation setting and are frequently cited by PHO respondents as specific educational need areas in recent surveys.

Whereas venous clots capture more attention among PHO providers, data suggest that arterial thrombosis occurs as commonly, often with devastating consequences. Similarly, heparin-induced thrombocytopenia (HIT) is infrequently recognized by PHO providers who are often ill-informed regarding appropriate diagnostic and management strategies. For bleeding patients, off-label use of certain treatment modalities (e.g., recombinant factor VIIa, inferior vena cava filters) has increased in recent years despite limited safety and efficacy data supporting such practice.

Introduction

Donald L. Yee, MD

Arterial Thrombosis: Lurking in the Background...and Ready to Strike

Leonardo R. Brandao, MD

Management of the Bleeding Patient: Evidence Informing Off-Label Considerations

Char M. Witmer, MD

Heparin-Induced Thrombocytopenia: Challenges and Controversies

Ellis J. Neufeld, MD PhD

(W02) Molecular Classification of Brain Tumors—Are We There Yet?

Moderator: Donald W. Parsons, MD PhD

Most pediatric oncologists treat children with brain tumors in a uniform manner based on histology. Unlike neuroblastoma and leukemia, where subsets are identified, all patients with a particular brain tumor like medulloblastoma are treated uniformly with radiation therapy and chemotherapy. Current attempts to reduce the dose of craniospinal radiation therapy in subsets of children with medulloblastoma are empiric. Significant advances have been made recently in understanding the biology of these patients. We will soon be classifying these diseases according to biologic risk factors as in neuroblastoma and leukemia and tailor therapy accordingly.

General oncologists will learn the data that will help them identify subsets of these patients who may be cured with less aggressive treatments and the subsets that require more aggressive therapies. They will understand the rationale behind such classifications and the biologic agents in development that can target pathways involved in the development of these tumors.

The Genomics of Pediatric High Grade Glioma: Moving Toward a Rational Molecular Classification

Donald W. Parsons, MD PhD

The Medulloblastoma Dialectic: Will the Real Medulloblastoma Please Stand Up?

Michael D. Taylor, MD PhD

BRAF in Pediatric Low Grade Glioma—Pathogenesis and Treatment

Charles G. Eberhart, MD PhD

7:30–9 pm

Corporate Forum Dinner Symposium

Preregistration is required for this session. For further information, please see page 12.

Division Directors' Meeting



Educational Program | Thursday, April 14

7–8:30 am

Concurrent Workshops

(W03) Preparing Successful Mentored Career Grant Applications

Moderators: Douglas K. Graham, MD PhD; Caroline A. Hastings, MD

The preparation of a successful mentored grant can greatly assist a clinical fellow in the transition to a junior faculty member. This session will provide Young Investigators insight into the successful preparation of mentored career grants in basic science research (K08) or patient-oriented research (K23). The session will begin with an interactive overview of grant writing tips and pitfalls. After this initial discussion, a mock grant review committee will demonstrate the grant review process and show how priority scores are generated. The mock grant review committee will emphasize strengths to highlight and obstacles to overcome in preparation of the mentored career grant.

Grant Writing Tips and Pitfalls

Douglas K. Graham, MD PhD

Mock Grant Review Committee

Jorge DiPaola, MD; Ellis J. Neufeld, MD PhD; Kathleen M. Sakamoto, MD PhD

(W04) Menorrhagia and Bleeding Disorders

Moderator: Lakshmi Venkateswaran, MD

Up to one-third of adolescent women are estimated to have menorrhagia. Although menorrhagia in teen-aged women may reflect the immaturity of the hypothalamic-pituitary-ovarian-uterine axis, underlying bleeding disorders have been described in 40% or more of this patient population. Currently, there is lack of uniformity among physicians in evaluating patients with menorrhagia for underlying bleeding disorders, resulting in underrecognition and suboptimal management of patients with bleeding disorders. There is a pressing need not only for standardization of evaluation and management strategies, but also for development of novel and appealing approaches that address the medical, educational, and psychosocial needs of these teenagers. This symposium will address the current controversies in the evaluation and recognition of bleeding disorders, explore the range of etiology for menorrhagia, and discuss the diagnostic modalities and various treatment approaches that are available for managing adolescents with menorrhagia.

Von Willebrand Disease—Cause or Association

Marilyn J. Manco-Johnson, MD

Platelet Function Disorders—Myth or Fact

Peter A. Kouides, MD

The Less Frequent Bleeding Disorders

Lakshmi Venkateswaran, MD

Gynecologist's Role in Diagnosis and Management

Andra James, MD MPH

8:45–10:45 am

Presidential Symposium

(S01) Above All, Do No Harm: Patient Safety and Quality Improvement in the Life-and-Death Moments of Pediatric Hematology/Oncology

Moderator: Jeffrey M. Lipton, MD PhD

To augment our responsibility to keep patients safe and pursue validated treatments our professional organization must take the lead within the burgeoning quality movement or risk having our processes dictated to us. This will be especially important to those who represent the future of our profession who undoubtedly will come to live with this as a permanent daily part of their practice

The quality movement is evolving, developing new metrics of what constitutes success and leveraging the appearance of computer medicine into its studies. We must take an active role in these considerations and gain possession of these tools on behalf of our patients in a proactive, not reactive fashion. Didactic discussion will highlight application of and requirement for the new science of quality for our profession. We will then offer a scientific symposium of presentations designed to place these studies as a centerpiece of our academic future.

Quality Initiatives: Proactive, Not Reactive

Lawrence C. Wolfe, MD

A Just Culture—Institutional Catalysis and Support for Quality

Arthur Klein, MD

QOPI—Specific Quality Initiatives for Hematology/Oncology

Joseph O. Jacobson, MD

Symposium on Quality

Amy L. Billett, MD

Moving Forward

Jeffrey M. Lipton, MD PhD

11:15 am–12:15 pm

Concurrent Platform Sessions I

12:30–2 pm

One-on-One Young Investigator Career Workshop Lunch

Moderators: Douglas K. Graham, MD PhD; Caroline A. Hastings, MD

Fellows and young investigators will have an opportunity to meet with a leader in the field of pediatric hematology/oncology. Two experts in each of the following fields will be available for the career discussions: clinical research—hematology, clinical research—oncology, basic science/translational research, health services/late effects, and clinician educator. A special interest table will be available for issues specific to foreign medical graduates. The purpose of this luncheon is to allow fellows and junior faculty to discuss issues one-on-one with

Educational Program | Thursday, April 14 (continued)

leaders in the field or questions related to career development in a small group setting. One to two discussion leaders will be placed per luncheon table. After 30 minutes of discussion, the YI participants will be invited to consider switching to a different table for further discussion. *Advance registration is required.*

(LCH) Clinical Research: Hematology

Thomas C. Abshire, MD; Neil Goldenberg, MD PhD

(LCO) Clinical Research: Oncology

Stephen P. Hunger, MD; A. Kim Ritchey, MD

(LBT) Basic Science/Translational Research

Patrick A. Zweidler-McKay, MD PhD; Markus Muschen, MD

(LCS) Health Services/Late Effects

Joseph P. Neglia, MD MPH; Gregory H. Reaman, MD

(LCE) Clinician/Educator

Elliott P. Vichinsky, MD; Naomi L. Luban, MD

(FMG) Foreign Medical Graduates

Sarah R. Vaiselbuh, MD; Ram Kalpatthi, MD

2:15–4:15 pm

Symposia

(S02) Young Investigator Symposium

Moderators: Caroline A. Hastings, MD; Emily Riehm Meier, MD

The importance of clinician educators in the provision of excellent clinical care and efficient, effective teaching is being more widely recognized. This symposium will provide skills for the clinician educator to become a more efficient educator and the necessary tools to build a comprehensive academic portfolio to ensure promotion. Clinical research opportunities for clinician educators will also be reviewed.

The 1-Minute Preceptor: Tips for Efficient Teaching During Morning Rounds

Michael F. Guerrero, MD

Academic Portfolio Building: How the Clinician-Educator Can Advance in Academia

Naomi L. Luban, MD

Scholarship Activities for the Clinician-Educator

Rima Jubran, MD

(S03) What the Dickens—It's ALiver Twist! Childhood Liver Cancer Symposium

Moderator: Leo Mascarenhas, MD MS

Primary childhood liver neoplasms comprise only 1.1% of malignancies in those <20 years of age. Approximately 100–150 children are diagnosed with liver cancer each year in the United States. Hepatoblastoma and hepatocellular carcinoma are the most common liver cancers seen in young children and adolescents, respectively. Certain conditions predispose to the development of hepatocellular carcinoma while the

etiology of hepatoblastoma is yet unknown. Surgical resection is the mainstay of curative therapy for liver cancers, but only one-third of newly diagnosed patients with liver tumors can be expected to have resectable disease at presentation.

Therefore, a multidisciplinary approach is required to attain optimal outcomes for childhood liver cancer. This symposium will discuss new developments in the epidemiology of liver tumors, review pathology and recent advancements in the biology, educate oncologists on surgical staging and the role of liver transplant, and discuss the results and plans for clinical trials in Children's Oncology Group and Childhood Liver Tumours Strategy Group (SIOPEL).

Introduction

Leo Mascarenhas, MD MS

Epidemiology

Logan G. Spector, PhD

Pathology and Molecular Pathways

Dolores Lopez-Terrada, MD PhD

Staging, Surgery, and Liver Transplant

Rebecka L. Meyers, MD FACS

Clinical Trials—SIOPEL Experience

Giorgio Perilongo, MD

Clinical Trials—North American Experience

Marcio H. Malogolowkin, MD

This symposium is supported by the Names Family Foundation.

4:45–5:45 pm

Young Investigator Award Presentations

Plenary Platform Session

5:45–6:45 pm

Author-Attended Poster Session A

5:45–7:30 pm

Grand Opening Reception with Exhibits and Posters

7:30–9 pm

Corporate Forum Dinner Symposium

Preregistration is required for this session. For further information, please see page 12.

Training Program Directors' Dinner Meeting

Advance registration is required.

Educational Program | Friday, April 15

7–8:30 am

Concurrent Workshops

(W05) Closing the Gap on Palliative Care

Moderator: Denise M. Adams, MD

Insight into pediatric palliative care (PPC) is vital for hematologists and oncologists, who frequently care for patients with pain and other distressing symptoms from chronic and life-threatening illnesses. Effective pain management is crucial for improving outcomes in patients with sickle cell diseases, for example, and of course is vitally important in the care of patients with malignancies, who often suffer from pain, fatigue, nausea, vomiting, and dyspnea, especially during the last weeks of life. Unfortunately, not every hematology/oncology center has access to a well-established PPC program, and few hematology/oncology training programs currently provide adequate exposure to this essential field.

The palliative care symposium at the 2009 ASPHO meeting generated interest and excitement. Both hematologists and oncologists expressed a desire for more opportunities to learn about PPC. This workshop will serve as a primer to an ASPHO palliative care agenda to improve this gap in knowledge.

Introduction

Denise M. Adams, MD

Innovations in Pain Management

Stefan J. Friedrichsdorf, MD

Panel

Linda D. Pegram, MD; Sarah Frieber, MD; Blaine B. Pitts, MD; Joanne Wolfe, MD MPH

(W06) Antimicrobial Prophylaxis in Pediatric Oncology: What's Old, What's New, and What's Coming?

Moderator: Sarah Alexander, MD

Infectious morbidity and mortality remains a significant problem in the care of children with cancer. Strategies for prevention of bacterial, fungal, and viral infections in pediatric oncology remain heterogeneous. A recent survey of supportive care in pediatric patients with acute myeloid leukemia (AML) from 227 pediatric oncology centers from six countries on three continents reported widely varying practices.

The availability of newer antifungal agents, sensitive viral detection methods, and adult data regarding antibacterial prophylaxis has made clinical decision making in children even more complex.

The goal of this session will be to review the current literature on infection prophylaxis in the pediatric oncology patients at highest risk for serious infection to allow participants an opportunity to reflect on their own clinical decision making and consider the need for further research.

Antibacterial Prophylaxis: For Whom, When, Why, and How Might It Be Useful

Sarah Alexander, MD

Prophylactic and Preemptive Antiviral Therapy: For Whom, with What, and When?

Brian T. Fisher, DO MSCE

Antifungal Prophylaxis: New Choices and New Data

Christopher C. Dvorak, MD

8:45–10:45 am

Symposia

(S04) Translational Medicine: Bone Marrow-Derived Stem Cells and the Tumor Microenvironment

Moderators: Sarah R. Vaiselbuh, MD; Leo Mascarenhas, MD MS

Emerging evidence shows the importance of the interaction of bone marrow-derived stem cells and the tumor microenvironment in the so-called stem cell niche.

Using neuroblastoma as a model, Dr. DeClerck will discuss how bone marrow-derived mesenchymal stem cells (MSC) play a role in contributing to a microenvironment that promotes osteolytic metastasis and tumor cell proliferation. Dr. Vaiselbuh will discuss MSC contribution to the leukemic stem cell niche. The concept of niche-induced oncogenesis might translate into new therapeutic targets to improve patient outcome.

MSCs are also currently employed in regenerative medicine and hematological transplantation. In addition, MSCs and hematopoietic stem cells have been shown to be amenable for reprogramming to pluripotency into induced pluripotent stem cells (iPS). An interesting population of pluripotent cells are very small embryonic-like stem cells (VSELs) recently identified in adult tissues, including the bone marrow. Dr. Ratajczak will discuss the current status of iPS and VSELs technology.

Bone Marrow Mesenchymal Stem Cells and Neuroblastoma Progression

Yves A. DeClerck, MD

Contribution of Bone Marrow Mesenchymal Stem Cells to the Leukemic Stem Cell Niche

Sarah R. Vaiselbuh, MD

Pluripotent Stem Cells: iPS and VSELs Technology in Hematopoietic Regenerative Medicine

Mariusz Ratajczak, MD PhD

(S05) Beyond the Big Three (Heparin, Warfarin, and Aspirin)—Newer Antithrombotic Agents in Development: Relevance for Pediatric Hematology

Moderator: Donald L. Yee, MD

The most commonly used antithrombotic agents in pediatrics have been in use for decades. Each has associated pitfalls, including poorly predictable dose response and bleeding risk that is not insignificant. Many newer agents in this therapeutic class have been developed in recent years that appear to have a more favorable drug profile. Some of these are already commercially available or soon will be for use in adults. However, development of these agents in the pediatric age group has lagged far behind, such that pediatric-specific data on these

Educational Program | Friday, April 15 (continued)

agents are sparse. In addition, familiarity with these agents and their often novel mechanisms of action among pediatric hematology/oncology providers remains low. More convenient dosing regimens and predictable dose response are among the potential advantages of these agents, and familiarity and experience with them is necessary to improve outcomes in pediatric patients requiring antithrombotic therapy.

Introduction and Approved but Not Quite Prime Time—Currently Available Antithrombotic Alternatives to the Big Three

Donald L. Yee, MD

Newer Oral Anticoagulants (Xa and Thrombin Inhibitors): Review of Adult Data and What They Mean for Pediatrics

Ronald J. Portman, MD FAAP FASN

Alternatives to Aspirin: Newer Antiplatelet Agents

Alan Michelson, MD

Aptamers as Anticoagulants: A Whole New Paradigm

Bruce A. Sullenger, PhD

10:45–11:15 am

Break with Exhibits and Posters

11:15 am–12:15 pm

Concurrent Platform Sessions II

12:30–1:45 pm

Author-Attended Poster Session B

1:45–3:45 pm

Symposia

(S06) Myeloid Malignancies: Molecular Pathogenesis and Targeted Therapies

Moderator: Kathleen M. Sakamoto, MD PhD

Acute myeloid leukemia (AML) is a heterogeneous disorder of transformed myeloid progenitor cells in which approximately 50% of patients do not have cytogenetic abnormalities. Treatment of AML is associated with significant morbidity and mortality. Less than 60% of children with AML survive. Therefore, it is critical to characterize the molecular defects that contribute to this disease to both understand the pathogenesis of AML and to identify new targets for therapy.

The Role of CREB in Myeloid Transformation and as a Target for AML Therapy

Kathleen M. Sakamoto, MD PhD

Signaling Pathways in JMML/AML

Benjamin Braun, MD PhD

Genomic and Proteomic Identification of Targets for AML Therapy

Kimberly Stegmaier, MD

(S07) Not Ravens but Dodos: Rare Birds in Pediatric Hematology

Moderator: Zora R. Rogers, MD

Recent advances in basic science and disease classification have shed light on mechanistic pathways and offered the promise of new treatment approaches in thrombotic microangiopathies (such as thrombotic thrombocytopenic purpura [TTP] and hemolytic uremic syndrome [HUS]), hereditary hemorrhagic telangiectasia (HHT), and autoimmune lymphoproliferative syndrome (ALPS). However, the infrequent occurrence of such rare entities limits provider experience and familiarity with these uncommon conditions, even among experts at referral centers. Pediatric hematology/oncology specialists are the primary consultants called upon to evaluate, recognize, and guide management of patients with the rare disorders to be discussed in this symposium. Recent member surveys have requested a review of these subjects at the annual meeting. Attendance at this symposium will result in increased recognition and understanding of the disorders, including their underlying physiology, and of promising treatment strategies.

Recent Developments at the Bench and Bedside

Zora R. Rogers, MD

TTP, HUS, and Other Thrombotic Microangiopathies in Children

David Motto, MD PhD

Hereditary Hemorrhagic Telangiectasia: What a Hot Hematology Topic!

Denise M. Adams, MD

TORing the ALPS: Targeting the mTOR Signaling Pathway in Autoimmune Lymphoproliferative Syndrome

David Teachey, MD

3:45–4 pm

Break with Exhibits and Posters

4–6 pm

Business Meeting and Award Presentations

- President's Remarks
- Frank A. Oski Memorial Lecture
- Distinguished Career Award

6–6:30 pm

Award Reception

6:30–7:30 pm

Battle of the Superstars

Educational Program | Saturday, April 16

7–8:30 am

Concurrent Workshops

(W07) Update on the Diagnosis, Evaluation, and Management of Histiocytic Disorders

Moderator: James A. Whitlock, MD

The rarity of histiocytic disorders presents formidable challenges to clinical investigation into their biology and management. Through international collaborative research efforts, Histiocyte Society-sponsored clinical trials have led to significant advances in the treatment and outcomes of children with these disorders. The goals of this workshop are to (1) provide participants with current, state-of-the-art information regarding the diagnosis, evaluation, and management of children with Langerhans cell histiocytosis (LCH) and hemophagocytic lymphohistiocytosis (HLH) based on results from recently completed international clinical trials for these disorders and to (2) update participants on ongoing and future clinical research into histiocytic disorders, including clinical trials for LCH and HLH and a web-based international registry for patients with rare histiocytic disorders.

Introduction

James A. Whitlock, MD

Update on Langerhans Cell Histiocytosis

Carlos Rodriguez-Galindo, MD

Update on Hemophagocytic Lymphohistiocytosis

Lisa H. Filipovich, MD

Introduction to the Histiocyte Society's International Rare Histiocytic Disorders Registry

Oussama Abba, MD

(W08) Practice Workshop: Improving Safety in Pediatric Hematology/Oncology

Moderator: Brian Weiss, MD

Quality improvement initiatives are now a requirement for certification, yet there is limited training in quality improvement science. This workshop, focusing on safety initiatives, will complement the Presidential Symposium. Improving safety and effectiveness of the care of children requires a transformational approach. Transformation involves setting system-level priorities, aligning measures with each priority, identifying targets, testing interventions, and spreading successful interventions throughout a division or organization. The work is not easy and requires cultural transformations such as recognition that safety is an issue, emphasizing that everyone is accountable for patient safety, and creating a culture where people are expected and encouraged to speak up in the face of uncertainty. Key drivers of transformation include leadership, building will, transparency, a business case for quality, patient and family engagement, improvement in infrastructure, improvement capability, and reliability and standardization.

The Cincinnati Children's Hospital Medical Center Safety Journey

Brian Weiss, MD

Panel

Eric J. Werner, MD; Amy L. Billett, MD; Marla H. Daves, MD; Janice F. Olson, MD

Breakout Session

Denise M. Adams, MD; Jeffrey Hord, MD; Brigitta U. Mueller, MD CPE MHCM; Scott C. Howard, MD

8:45–10:45 am

Symposia

(S08) New Aspects of Neuroblastoma Treatment

Moderator: Peter Zage, MD PhD

Neuroblastoma is the most common extracranial solid tumor of childhood, and the outcomes of children with high-risk and relapsed disease remain poor. However, new international strategies for risk stratification and for treatment based on novel targets and immune therapy are currently being employed to standardize and improve the outcomes of children with neuroblastoma worldwide.

A new international neuroblastoma risk classification system (the International Neuroblastoma Risk Group Staging System) has been developed and will be incorporated into national and international clinical trials soon, resulting in significant changes in the initial evaluation and subsequent treatment of neuroblastoma patients. Furthermore, novel treatments are currently being developed based on a better understanding of neuroblastoma biology and on the recruitment of the immune system to specifically target neuroblastoma tumors. These approaches will dramatically enhance the options available for treatment of children with neuroblastoma.

Introduction and the Role of Immunotherapy for Neuroblastoma—A Little Alphabet Soup

Peter Zage, MD PhD

The International Neuroblastoma Risk Group (INRG) Classification System: Past, Present, and Future

Susan Cohn, MD

Discovery and Exploitation of Molecular Targets in Neuroblastoma

Yael P. Mosse, MD

(S09) Pediatric Highlights of the BMT Tandem Meetings

Moderator: Kirk R. Schultz, MD

Blood and marrow transplantation (BMT) is an increasingly utilized treatment modality for both malignant and nonmalignant pediatric disorders. Over the past decade, stem cell sources have been expanded to include single and double umbilical cord blood units, peripheral blood stem cells, growth factor mobilized bone marrow stem cells, and selective cell populations. Conditioning regimens and supportive care

Educational Program | Saturday, April 16 (continued)

strategies have evolved based on underlying disease pathophysiology and studies done to provide safer transplants with better outcomes and lowered toxicity. It is imperative that pediatric hematologists/oncologists remain current on advances in the field and understand the indications, methods, and optimal timing of incorporating transplantation into the overall treatment plan for their patients. This unique session will feature three cutting-edge topics from the Pediatric Program Day of the 2011 BMT Tandem meetings.

Fanconi Anemia and Transplantation

Margaret MacMillan, MD

Children with CML—Treat or Transplant?

Kirk R. Schultz, MD

Chronic Granulomatous Disease: Pathophysiology and Therapy

Morton J. Cowan, MD

This symposium is supported in part by the American Society for Blood and Marrow Transplantation.

11:15 am–1:15 pm

Symposia

(S10) Transfusion Medicine Problems and Solutions for the General Pediatric Hematologist/Oncologist

Moderator: Sumit Gupta, MD

This symposium will focus on areas of transfusion medicine relevant to the everyday practice of the general pediatric hematologist and oncologist. This area has been identified as a significant education gap by ASPHO members in past surveys. Dr. Eileen McBride will review the current approach to and management of platelet refractoriness, a topic commonly encountered by both hematologists and oncologists. Dr. Jason Ford will present case scenarios involving transfusion challenges in patients undergoing allogeneic stem cell transplant. Finally, Dr. Naomi Luban will explore the incidence of alloimmunization in children with sickle cell disease and thalassemia and the evidence linking this to adverse clinical outcomes. Controversies surrounding routine extended red cell phenotyping and matching will be examined. Using interactive techniques with the audience, the speakers will lead listeners through the workup and management of these cases.

Introduction and Cases

Sumit Gupta, MD

Platelet Refractoriness

Eileen R. McBride, MD FRCPC

Transfusion Issues in the Stem Cell Transplant Period

Jason Ford, MD FRCPC

Alloimmunization in Children Undergoing Chronic Transfusion

Naomi L. Luban, MD

(S11) Many Pathways In Pediatric Hematology and Oncology Lead to mTOR

Moderator: Judith F. Margolin, MD

mTOR activation/inhibition has been found to be important in the pathogenesis of multiple oncologic, hematologic, and vascular problems. This symposium will explore both the basic science of mTOR and related pathways, and discuss various pediatric hematology/oncology disease states where mTOR inhibitors have been found to be useful. Attendees of this symposium can expect to improve their knowledge base regarding mTOR-related disease, become informed about the latest in experimental protocols utilizing mTOR inhibitors, and learn about when and whether to consider using mTOR inhibitors to treat a variety of disease entities.

Why Clinicians Need to Know About mTOR

Judith F. Margolin, MD

mTOR 101 and Beyond: The Basic Science of mTOR and Related Pathways

George Thomas, PhD

mTOR Inhibitors to Treat Leukemia and Lymphomas

Stephan Grupp, MD PhD

mTOR Inhibitors in NF and NF-Related Tumors

Brian Weiss, MD

mTOR Inhibitors in Vascular Malformations

Denise M. Adams, MD

Posters

The 24th Annual Meeting will feature two author-attended poster sessions. Chosen from a large number of submissions, the posters will represent the best innovations and research in the study and treatment of pediatric hematology/oncology. Poster abstracts selected for presentation at the Annual Meeting will be published online in a searchable database and in a *Pediatric Blood & Cancer* journal supplement. This will allow registrants to plan their poster viewing in advance of the meeting. The abstracts are scheduled to be available in March 2011. To search and view the abstracts, visit the American Society of Pediatric Hematology/Oncology website at www.aspho.org.

Faculty

Oussama Abia, MD

Hospital for Sick Children
Toronto, ON, Canada

Thomas C. Abshire, MD

Blood Center of Wisconsin
Milwaukee, WI

Denise M. Adams, MD

Cincinnati Children's Hospital Medical Center
Cincinnati, OH

Sarah Alexander, MD

Hospital for Sick Children
Toronto, ON, Canada

Amy L. Billett, MD

Dana-Farber Cancer Institute/Children's Hospital
Boston
Boston, MA

Leonardo R. Brandao, MD

Hospital for Sick Children
Toronto, ON, Canada

Benjamin Braun, MD PhD

University of California–San Francisco
San Francisco, CA

Susan Cohn, MD

University of Chicago
Chicago, IL

Morton J. Cowan, MD

University of California–San Francisco
San Francisco, CA

Maria H. Daves, MD

Texas Children's Cancer Center
Houston, TX

Yves A. DeClerck, MD

Children's Hospital Los Angeles
Los Angeles, CA

Jorge DiPaola, MD

The Children's Hospital Denver
Aurora, CO

Christopher C. Dvorak, MD

University of California–San Francisco
San Francisco, CA

Charles G. Eberhart, MD PhD

Johns Hopkins University School of Medicine
Baltimore, MD

Lisa H. Filipovich, MD

Cincinnati Children's Hospital Medical Center
Cincinnati, OH

Brian T. Fisher, DO MSCE

Children's Hospital of Philadelphia
Philadelphia, PA

Jason Ford, MD FRCPC

BC Children's Hospital
Vancouver, BC, Canada

Sarah Friebert, MD

Akron Children's Hospital
Akron, OH

Stefan J. Friedrichsdorf, MD

Children's Hospitals and Clinics of Minnesota
Minneapolis, MN

Neil Goldenberg, MD PhD

The Children's Hospital Denver
Aurora, CO

Douglas K. Graham, MD PhD

The Children's Hospital Denver
Aurora, CO

Stephan Grupp, MD PhD

Children's Hospital of Philadelphia
Philadelphia, PA

Michael F. Guerrero, MD

Children's National Medical Center
Washington, DC

Sumit Gupta, MD

Hospital for Sick Children
Toronto, ON, Canada

Caroline A. Hastings, MD

Children's Hospital of Oakland
Oakland, CA

Jeffrey Hord, MD

Akron Children's Hospital
Akron, OH

Scott C. Howard, MD

St. Jude Children's Research Hospital
Memphis, TN

Stephen P. Hunger, MD

The Children's Hospital Denver and University
of Colorado School of Medicine
Aurora, CO

Joseph O. Jacobson, MD

North Shore Medical Center
Salem, MA

Andra James, MD MPH

Duke University Medical Center
Durham, NC

Rima Jubran, MD

Children's Hospital Los Angeles
Los Angeles, CA

Ram Kalpathi, MD

Medical University of South Carolina
Mount Pleasant, SC

Arthur Klein, MD

Steven & Alexandra Cohen Children's Medical
Center
New Hyde Park, NY

Peter A. Kouides, MD

University of Rochester
Rochester, NY

Jeffrey M. Lipton, MD PhD

Steven & Alexandra Cohen Children's Medical
Center
New Hyde Park, NY

Mignon Loh, MD

University of California–San Francisco
San Francisco, CA

Dolores Lopez-Terrada, MD PhD

Baylor College of Medicine
Houston, TX

Naomi L. Luban, MD

Children's National Medical Center
Washington, DC

Margaret MacMillan, MD

University of Minnesota
Minneapolis, MN

Marcio H. Malogolowkin, MD

Children's Center for Cancer
Los Angeles, CA

Marilyn J. Manco-Johnson, MD

University of Colorado Denver
Aurora, CO

Judith F. Margolin, MD

Baylor College of Medicine
Houston, TX

Leo Mascarenhas, MD MS

Children's Hospital Los Angeles
Los Angeles, CA

Eileen R. McBride, MD FRCPC

IWK Health Centre, Dalhousie University
Halifax, NS, Canada

Rebecka L. Meyers, MD FACS

University of Utah
Salt Lake City, UT

Alan Michelson, MD

Children's Hospital Boston
Boston, MA

Yael P. Mosse, MD

Children's Hospital of Philadelphia
Philadelphia, PA

David Motto, MD PhD

University of Iowa
Iowa City, IA

Brigitta U. Mueller, MD CPE MHCM

Baylor College of Medicine
Houston, TX

Markus Muschen, MD

University of Southern California
Los Angeles, CA

Joseph P. Neglia, MD MPH

University of Minnesota
Minneapolis, MN

Ellis J. Neufeld, MD PhD

Children's Hospital Boston
Boston, MA

Janice F. Olson, MD

Legacy Emanuel Hospital and Health
Portland, OR

Donald W. Parsons, MD PhD

Baylor College of Medicine
Houston, TX

Linda D. Pegram, MD

Children's Hospital of the King's Daughters
Norfolk, VA

Giorgio Perilongo, MD

University of Padua
Padua, Italy

Blaine B. Pitts, MD

Cincinnati Children's Hospital Medical Center
Cincinnati, OH

Ronald J. Portman, MD FAAP FASN

Bristol-Myers Squibb
Princeton, NJ

Mariusz Ratajczak, MD PhD

University of Louisville
Louisville, KY

Gregory H. Reaman, MD

Children's National Medical Center
Washington, DC

Emily Riehm Meier, MD

Children's National Medical Center
Washington, DC

A. Kim Ritchey, MD

Children's Hospital of Pittsburgh
Pittsburgh, PA

Carlos Rodriguez-Galindo, MD

Dana-Farber Cancer Institute
Boston, MA

Zora R. Rogers, MD

University of Texas Southwestern Medical Center
Dallas, TX

Kathleen M. Sakamoto, MD PhD

David Geffen School of Medicine at UCLA
Los Angeles, CA

Kirk R. Schultz, MD

BC Children's Hospital/University of BC
Vancouver, BC, Canada

Logan G. Spector, PhD

University of Minnesota
Minneapolis, MN

Kimberly Stegmaier, MD

Dana-Farber Cancer Institute
Boston, MA

Bruce A. Sullenger, PhD

Duke University Medical Center
Durham, NC

Michael D. Taylor, MD PhD

Hospital for Sick Children
Toronto, ON, Canada

David Teachey, MD

Children's Hospital of Philadelphia
Philadelphia, PA

George Thomas, PhD

University of Cincinnati
Cincinnati, OH

Sarah R. Vaiselbuh, MD

Steven & Alexandra Cohen Children's Medical
Center
New Hyde Park, NY

Lakshmi Venkateswaran, MD

Texas Children's Hospital/Baylor College of Medicine
Houston, TX

Elliott P. Vichinsky, MD

Children's Hospital Oakland
Oakland, CA

Brian Weiss, MD

Cincinnati Children's Hospital Medical Center
Cincinnati, OH

Eric J. Werner, MD

Children's Hospital of King's Daughters
Norfolk, VA

James A. Whitlock, MD

Hospital for Sick Children
Toronto, ON, Canada

Char M. Witmer, MD

Children's Hospital of Philadelphia
Philadelphia, PA

Joanne Wolfe, MD MPH

Children's Hospital Boston
Boston, MA

Lawrence C. Wolfe, MD

Steven & Alexandra Cohen Children's Medical
Center
New Hyde Park, NY

Donald L. Yee, MD

Baylor College of Medicine
Houston, TX

Peter Zage, MD PhD

MD Anderson Cancer Center
Houston, TX

Patrick A. Zweidler-McKay, MD PhD

MD Anderson Cancer Center
Houston, TX

Corporate Forum Symposia

Independently sponsored corporate forum symposia are offered in conjunction with the ASPHO 24th Annual Meeting. The programs have been reviewed and approved by the 2011 ASPHO Program Committee to ensure they are relevant to the audience and that they do not duplicate the official ASPHO program.

These satellite symposia are open to registrants of the 2011 Annual Meeting at no additional charge, although preregistration is required. Seating is available to those responding on a first-come, first-served basis.

Wednesday, April 13

7:30–9 pm

Corporate Forum Dinner Symposium

From Perception to Reality: Plasma-Derived Clotting Concentrates in Clinical Context

Thomas C. Abshire, MD; Albert Farrugia, PhD, Srinivas V. Kaveri, PhD; Peter A. Kouides, MD

This symposium will consider the safety of plasma-derived clotting factors for the treatment of von Willebrand disease, hemophilia A, and hemophilia B. In addition, this symposium will look at recent experimental data suggesting that the presence of von Willebrand factor (VWF) in plasma-derived factor VIII/VWF concentrates modulates immunogenicity of FVIII replacement therapy.

This activity will be planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Education (ACCME) through the joint sponsorship of the University of Cincinnati School of Medicine and The Exeter Group. The University of Cincinnati School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati School of Medicine designates this activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This symposium is supported through an educational grant from Grifols, USA, LLC.

There is no registration fee for attending this symposium, however, seating is limited. To preregister for this symposium, please register online at www.symposiareg.org/aspho or contact Mary Paulson at 847.375.4803. Preregistration does not guarantee seating. We do recommend arriving at the symposium location early.

Thursday, April 14

7:30–9 pm

Corporate Forum Dinner Symposium

Current Strategies for the Surgical Management of Patients with Congenital Bleeding Disorders

Victor S. Blanchette, MD; Steven W. Pipe, MD; Meera Chitlur, MD

The management of patients with congenital bleeding disorders presents a clinical challenge when a surgical procedure is indicated and these patients may be at risk for poorer outcomes. Although there is accumulated experience in patients undergoing orthopedic surgery, new nonorthopedic clinical considerations and patient management issues are now evolving due to improved factor replacement therapy, diagnostic tools, and increased clinical experience. This symposium will provide both current evidence and expert opinion on developing presurgical strategies for improving outcomes and overall quality of life for these patients.

This activity will be planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM), the Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. PIM is accredited by the ACCME to provide continuing medical education for physicians.

PIM designates this activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This symposium is supported through an educational grant from Novo Nordisk, Inc.

Please visit us at www.bloodcmecenter.org to learn more about this event.

There is no registration fee for attending this symposium, however, seating is limited. To preregister for this symposium, please register online at www.symposiareg.org/aspho or contact Mary Paulson at 847.375.4803. Preregistration does not guarantee seating. We do recommend arriving at the symposium location early.

ASPHO Thanks Our 2011 Corporate Members

genzyme

GRIFOLS

NOVARTIS
ONCOLOGY


novo nordisk®

Thank You ASPHO Program Committee

Jorge DiPaola, MD, Chair
The Children's Hospital Denver
Aurora, CO

**Douglas K. Graham, MD
PhD, Vice Chair**
The Children's Hospital Denver
Aurora, CO

**Judith F. Margolin, MD,
Past Chair**
Baylor College of Medicine
Houston, TX

Denise M. Adams, MD
Cincinnati Children's Hospital
Medical Center
Cincinnati, OH

**Jacqueline N. Casillas, MD
MSHS**
David Geffen School of
Medicine at UCLA
Los Angeles, CA

Murali M. Chintagumpala, MD
Baylor College of Medicine
Houston, TX

Sinisa Dovat, MD DSc
Penn State
Hershey, PA

Sumit Gupta, MD
Hospital for Sick Children
Toronto, ON, Canada

Caroline A. Hastings, MD
Children's Hospital of Oakland
Oakland, CA

Leo Mascarenhas, MD MS
Children's Hospital Los Angeles
Los Angeles, CA

Zora R. Rogers, MD
University of Texas
Southwestern Medical
Center
Dallas, TX

Sarah R. Vaiselbuh, MD
Steven and Alexandra Cohen
Children's Medical Center
New Hyde Park, NY

Leonard A. Valentino, MD
Rush University Medical Center
Chicago, IL

Daniel S. Wechsler, MD PhD
Duke University Medical
Center
Durham, NC

Donald L. Yee, MD
Baylor College of Medicine
Houston, TX

Peter Zage, MD PhD
MD Anderson Cancer Center
Houston, TX

Handout Materials and Audio Recordings

Registrants can access and view handout materials online. ASPHO will not print a paper syllabus of speakers' handouts. Poster and paper abstracts will be available online approximately 1 month before the meeting at www.aspho.org/education/content/meeting. ASPHO is excited to offer Annual Meeting attendees complimentary online access to the audio recordings and slide presentations of speakers' lectures from the meeting for a limited time. After the meeting, the recordings will be available on the ASPHO website beginning in **May**. Meeting registrants will receive an e-mail in or before **May** with a unique password and instructions about how to access the online recordings.

Exhibit Schedule

Thursday, April 14

8 am–4 pm.....Exhibit Setup and Registration
5:45–7:30 pmOpening Reception with Exhibits

Friday, April 15

10:45 am–4 pm.....Exhibits Open
10:45–11:15 amConference Break
12:30–1:45 pm.....Exhibits Open
3:45–4 pmConference Break
4–7 pmExhibit Teardown

Schedule as of October 2010, subject to change.



Travel Information

Baltimore

Baltimore's rich history, diverse city, and beautiful harbor make it an ideal destination. There is so much to do within walking distance of the hotel. Enjoy numerous museums and theatres, attractions around every corner, and shopping and dining. Getting there can be half the fun with water taxis, trolley tours, and paddle boats. Although it is known for its seafood, Baltimore has many emerging culinary hotspots. Once you get a taste of Baltimore, you won't want to leave! For more information on Baltimore, visit www.baltimore.org.



Housing

A block of rooms is being held for ASPHO meeting attendees at the following hotel:

Hilton Baltimore

401 West Pratt Street
Baltimore, MD 21201

Reservations: 1.800.HILTONS or www.aspho.org

Room rate: \$209 single/double

Cutoff date: Monday, February 28, 2011

Please visit the ASPHO website at www.aspho.org to make your reservations online. Be sure to indicate you are attending the 24th Annual Meeting of the American Society of Pediatric Hematology/Oncology to receive the conference rate.

A deposit will be required to hold reservations. A cancellation penalty will be charged for rooms canceled within 72 hours prior to arrival. For room blocks of five or more, payment is required in advance to hold the reservation. There is a 3-night minimum on blocks of five or more rooms held at conference rate.

Ground Transportation

The Hilton Baltimore is located approximately 15 minutes from the Baltimore/Washington International Airport. Taxis average \$25–\$30 each way. SuperShuttle is also available for approximately \$20 per person. For more information on shuttles or to make a reservation, please call 800.BLUE.VAN (800.258.3826). Parking is also available at the Hilton Baltimore; daily parking rates apply.

Airlines

UNITED is offering special meeting discounts for attendees of the ASPHO 24th Annual Meeting. Simply call (or have your travel agent call) our Special Meeting Desk at 1.800.521.4041 and refer to Meeting ID Number 550KO to receive a 5% discount off applicable fares. Use this Meeting ID to get special fares on United and Lufthansa.

ASPHO Membership Information

ASPHO is the only organization exclusively for and about pediatric hematology/oncology that fosters collaborations to develop optimal treatments for children with blood disorders and cancer.

Why join ASPHO? The member benefits include

- a member discount of up to \$175 on the annual conference registration fee
- a monthly subscription to *Pediatric Blood & Cancer*, the official journal of ASPHO
- a bimonthly e-newsletter that provides current news and information of interest to members
- access to the ASPHO Online Member Community, which offers networking opportunities and the ability to share information, documents, links, and files related to optimal treatments and best practices in an organized searchable library
- an annual printed membership directory (in addition to an online directory resource) to help locate and connect with other professionals working in the field of pediatric hematology/oncology.

ASPHO membership must be endorsed and signed for by a current member of ASPHO in good standing. This signature must be included in Box A of the registration form to complete the registration process.

Trainees must provide a letter of recommendation from their training program director. If you are a Trainee applying for membership, please include this recommendation with your registration form.

ASPHO 2011 Annual Meeting Registration Form

April 13-16, 2011 | Baltimore, MD | Hilton Baltimore

FOR OFFICE USE ONLY

Cust # _____ Mtg Ord #3- _____

Date _____

Please print. Use a separate form for each registrant. Duplicate as necessary.

Complete Name _____ First Name for Badge _____

Facility _____ Facility City/State _____

Preferred Address (Home Office) _____ City/State/ZIP _____

Home Phone _____ Office Phone _____ Fax _____

E-mail* (required) (Home Office) _____ (FTA) Check here if this will be your first ASPHO Conference.

Emergency Contact Name _____ Day Phone _____ Evening Phone _____

*You will receive an e-mail confirmation of your registration when it has been processed.

To register, make your selections in the boxes below, add the subtotals, and indicate the total amount in box F.

Conference Registration		A	
	On or before	After	
Member Rates	3/1/11	3/1/11	
Regular Member (M)	<input type="checkbox"/> \$450	<input type="checkbox"/> \$530	
Affiliate Member (MA)	<input type="checkbox"/> \$275	<input type="checkbox"/> \$355	
Trainee Member (MT)	<input type="checkbox"/> \$150	<input type="checkbox"/> \$230	
Emeritus Member (ME)	<input type="checkbox"/> \$175	<input type="checkbox"/> \$255	
Join & Register Rates (add dues in Box B)			
<i>ASPHO membership requires endorsement from a current ASPHO member. This signature must be included below for your registration to be processed. For more information about endorsement or if you are a Trainee, please refer to page 14.</i>			
Active Member (JR)	<input type="checkbox"/> \$450	<input type="checkbox"/> \$530	
Affiliate Member (JRA)	<input type="checkbox"/> \$275	<input type="checkbox"/> \$355	
Trainee Member (JRT)	<input type="checkbox"/> \$150	<input type="checkbox"/> \$230	
Member Endorsement (Required to join ASPHO)			
Member Name (please print) _____			
Member Signature _____ Date _____			
Nonmember Rates			
Nonmember (N)	<input type="checkbox"/> \$625	<input type="checkbox"/> \$705	
Affiliate Nonmember (NA)	<input type="checkbox"/> \$350	<input type="checkbox"/> \$430	
Trainee Nonmember (NT)	<input type="checkbox"/> \$200	<input type="checkbox"/> \$280	
Additional Rates*			
SIOP Member (SM)	<input type="checkbox"/> \$550		
Physician From Developing Country (CD)	<input type="checkbox"/> \$200		
<i>*Only available by phone, fax, or mail. Verification will be made before registration is processed.</i>			
Subtotal A \$ _____			

Membership Dues		B	
Active Member	<input type="checkbox"/> \$335	Trainee Member	
Affiliate Member		First-year fellow	<input type="checkbox"/> no charge
Without optional journal	<input type="checkbox"/> \$50	Second-year fellow	<input type="checkbox"/> no charge
With optional journal	<input type="checkbox"/> \$75	Third-year fellow	<input type="checkbox"/> no charge
<i>ASPHO membership requires endorsement from a current ASPHO member. This signature must be included in Box A for your registration to be processed. For more information about endorsement or if you are a Trainee, please refer to page 14.</i>			
		Fourth-year fellow	<input type="checkbox"/> \$115
		Fifth-year fellow	<input type="checkbox"/> \$115
Subtotal B \$ _____			

Special Requests	C
<input type="checkbox"/> I will be using a wheelchair at the conference. (SA)	
<input type="checkbox"/> I will need a vegetarian meal. (SDV)	
<input type="checkbox"/> I do not wish to have my name and contact information included in the on-site attendee list. (DIS)	

Photography Disclosure: Photographs may be taken of participants of ASPHO's 2011 Annual Meeting. These photos are for ASPHO use only and may appear on ASPHO's website, in printed brochures, or other promotional materials. Attendee registration grants ASPHO permission and consent for use of this photography.

Session Registration		D	
<i>Please note the following workshops you plan to attend. See page 3 for session codes.</i>			
Wednesday, April 13		Friday, April 15	
5:30-7 pm	<input type="checkbox"/> W <input type="checkbox"/> 0	7-8:30 am	<input type="checkbox"/> W <input type="checkbox"/> 0
Thursday, April 14		8:45-10:45 am	<input type="checkbox"/> S <input type="checkbox"/> 0
7-8:30 am	<input type="checkbox"/> W <input type="checkbox"/> 0	1:45-3:45 pm	<input type="checkbox"/> S <input type="checkbox"/> 0
2:15-4:15 pm	<input type="checkbox"/> S <input type="checkbox"/> 0	Saturday, April 16	
		7-8:30 am	<input type="checkbox"/> W <input type="checkbox"/> 0
		8:45-10:45 am	<input type="checkbox"/> S <input type="checkbox"/> 0
		11:15 am-1:15 pm	<input type="checkbox"/> S <input type="checkbox"/> 1

Optional Event Registration		E	
Thursday, April 14			
12:30-2 pm	One-on-One Young Investigator Career Lunch Workshop* \$15		
<i>(Limited to the first 80 registrants)</i>			
Please select one topic for your table assignment:			
<input type="checkbox"/> Basic Science/Translational Research (LBT)	<input type="checkbox"/> Clinical Research: Hematology (LCH)		
<input type="checkbox"/> Clinical Research: Oncology (LCO)	<input type="checkbox"/> Health Services/Late Effects (LCS)		
<input type="checkbox"/> Clinician/Educator (LCE)			
<input type="checkbox"/> Foreign Medical Graduates (FMG)			
*Attendance limited to Young Investigators only.			
7:30-9 pm	Training Program Directors' Dinner Meeting (PDD)	<input type="checkbox"/> \$50	
*Attendance limited to Program Directors only.			
			Subtotal E \$ _____

4 Easy Ways to Register	
Mail	ASPHO Meeting PO Box 839 Glenview, IL 60025-0839
Phone*	847.375.4716
Fax*	866.585.0477
Online*	www.aspho.org
<i>*credit card payment only</i>	

(A + B + E) = \$ _____ **Total F**

Payment	
All funds must be submitted in U.S. dollars.	
<input type="checkbox"/> Visa	<input type="checkbox"/> MasterCard
<input type="checkbox"/> Discover	<input type="checkbox"/> American Express
<input type="checkbox"/> Check	
If payment does not accompany this form, your registration will not be processed.	
* Make checks payable to ASPHO. Checks not in U.S. funds will be returned.	
* A charge of \$50 will apply to checks returned for insufficient funds.	
* If rebilling of a credit card charge is necessary, a \$75 processing fee will be charged.	
* I authorize ASPHO to charge the above-listed credit card amounts reasonably deemed by ASPHO to be accurate and appropriate.	
Account number	Exp. date
Cardholder's name (print)	Signature

Cancellation Policy: All cancellations must be made in writing. A \$100 processing fee will be charged for all cancellations postmarked more than 14 days before the event. No refunds will be made under any circumstances on cancellations postmarked after March 30, 2011. ASPHO reserves the right to substitute faculty or to cancel or reschedule sessions due to low enrollment or other unforeseen circumstances. If ASPHO must cancel the entire meeting, registrants will receive a full credit or refund of their paid registration fee. No refunds can be made for lodging, airfare, or any other expenses related to attending the meeting.



Consider these reasons for attending **the 24th Annual ASPHO Meeting.**

- 23.25 hours of CME credit are available to attendees.
- Baltimore is a city famous for its beautiful waterfront, world-class museums, and three centuries of history.
- April in Baltimore is beautiful, with an average temperature of 65 degrees.
- The room rate at the Hilton Baltimore for the conference is only \$209.
- There are more than 25 sessions to choose from.
- The opening session will be “Above All, Do No Harm: Patient Safety and Quality Improvement in the Life-and-Death Moments of Pediatric Hematology/Oncology.”
- The Legends will defend their title in the Battle of the Superstars.
- You will have access to a diverse and exceptionally experienced faculty.
- This year’s conference will include four Young Investigator sessions.